3-FEA
3-fluoro-N-ethylamphetamine
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
3-FEA (N-ethyl-1-(3-fluorophenyl)propan-2-amine) is an emerging synthetic stimulant-empathogen of the substituted amphetamine class. It is the N-ethyl homolog of 3-fluoroamphetamine, with greater serotonin weighting that pulls its character toward entactogenic territory. 3-FEA is a triple monoamine releasing agent, producing its effects by reversing dopamine, norepinephrine, and serotonin transporters to flood synapses with all three transmitters.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, MDMA, cathinones +3 moreamphetamine, MDMA, cathinones, 4-FA, 3-FA, serotonergic compounds show less
First identified from a Spanish law enforcement seizure in July 2017 and characterized via forensic spectroscopy,[3] 3-FEA belongs to a wave of fluorinated amphetamine analogs that appeared on research chemical markets from approximately 2010 onward.[4] Germany scheduled it pre-emptively in 2016, before any published scientific identification. It circulates exclusively through online vendors — no street-market presence has been documented.
Subjective effects include stimulation, emotional warmth, tactile enhancement, euphoria, and paradoxical sedation. The experience occupies a middle ground between pure stimulants and entactogens — serotonin-driven body warmth and openness layered over residual catecholamine drive, with route of administration shifting the balance.[5] Appetite suppression, insomnia, and post-use mood deflation are characteristic unsought effects.
Physical dependence has been demonstrated in mice after seven days of repeated dosing.[1] Cardiovascular toxicity is the primary acute concern — the related 4-fluoroamphetamine produced severe cardiac complications in 40% of emergency presentations.[6] 3-FEA is among the least-studied compounds in active recreational circulation: no human pharmacological data, no clinical trials, and no transporter binding affinities have been published.
History[edit]
History
Discovery
3-FEA was first scientifically identified from a fine white-yellowish powder seized by Spanish police in July 2017. Forensic analysts characterized it as 3-fluoroethamphetamine hydrochloride using infrared spectroscopy, mass spectrometry, and nuclear magnetic resonance.[3] CAS registry numbers predating this seizure indicate earlier synthetic work, though no publication documents the original synthesis or its purpose.
Market emergence
The compound belongs to a systematic exploration of fluorinated amphetamine positional isomers (2-FA, 3-FA, 4-FA and their N-methyl and N-ethyl homologs) that emerged on research chemical markets from approximately 2010 as unscheduled alternatives to controlled stimulants.[4] Distribution has occurred exclusively through online vendors, including sale in pellet form alongside its positional isomer 2-FEA.[5] No street-level market presence has been documented.
Research status
As of 2026, only one primary research study has directly investigated 3-FEA: Jo et al. (2024) administered it to mice and documented withdrawal-induced hyperactivity and depression-like behaviors, concluding that repeated administration produces physical dependence.[1] No human pharmacological study or clinical trial has been published. Germany scheduled the compound under its NPS law in November 2016 — before the first published forensic identification — indicating regulatory awareness through intelligence channels.[7]
The name "3-FEA" follows research chemical naming convention: the number indicates fluorine ring position (meta), "F" for fluorine, "E" for the N-ethyl group, and "A" for amphetamine. This systematic naming distinguishes it from its positional isomers 2-FEA and 4-FEA. The compound has no street names or cultural identity beyond the research chemical community, where it is discussed primarily as a functional comparison point to the more popular 4-FA.
Chemistry[edit]
Chemistry
Structure
3-FEA is a substituted amphetamine bearing a fluorine atom at the meta position of the phenyl ring and an N-ethyl group on the amine nitrogen. The parent scaffold is the phenethylamine backbone with an α-methyl group (defining the amphetamine class). This places it in a family of fluorinated N-alkylamphetamines alongside 4-fluoroamphetamine and 2-FEA.
The compound is the N-ethyl homolog of 3-fluoroamphetamine (3-FA). This structural relationship carries pharmacological significance: N-ethylation of amphetamine-class compounds consistently shifts monoamine release selectivity toward serotonin relative to dopamine, as demonstrated across the MDA→MDE and amphetamine→ethylamphetamine series.[8]
| Molecular formula (free base) | C₁₁H₁₆FN |
| Molecular weight (free base) | 181.25 g/mol |
| Molecular formula (HCl salt) | C₁₁H₁₇ClFN |
| Molecular weight (HCl salt) | 217.71 g/mol |
Stereochemistry
The molecule contains one chirality center at the α-carbon.[9] Commercial material circulates as a racemic mixture — enantioseparation has been confirmed using protein-based HPLC.[10] No published data compare the pharmacological activity of individual enantiomers. By analogy with amphetamine, the S-(+) enantiomer is expected to carry the majority of stimulant activity.inferred
Physical properties
3-FEA hydrochloride appears as a white to yellowish crystalline powder in seized samples.[3] The carbon-fluorine bond at the meta position is metabolically stable — defluorination is not expected under normal physiological conditions. No published melting point data exist.
Structure-activity relationships
Three structural features define 3-FEA's pharmacological position:
- Meta-fluorine: The 3-position fluorine distinguishes 3-FEA from 4-fluoroamphetamine (para position). Meta substitution on fluoroamphetamines shifts the dopamine/serotonin balance relative to para.[11][12]
- N-ethyl group: Increases serotonin release selectivity relative to the N-unsubstituted parent (3-FA), paralleling the MDA→MDE shift.[8]
- α-methyl group: Defines amphetamine class membership, conferring oral activity and resistance to monoamine oxidase-mediated degradation.
Pharmacology[edit]
Pharmacology
Mechanism of action
3-FEA functions as a triple monoamine releasing agent. It enters presynaptic neurons via carrier-mediated uptake at the DAT (DAT), NET (NET), and SERT (SERT), then reverses transporter direction to push stored monoamines into the synaptic cleft.[1][2] This mechanism produces a rapid, pronounced elevation of all three monoamines — distinct from reuptake inhibitors, which merely slow clearance.
The pharmacological profile is characterized as serotonin-dominant relative to 3-fluoroamphetamine (3-FA). This characterization rests on the established principle that N-ethyl substitution on amphetamine analogs reduces dopamine release potency while maintaining or enhancing serotonin release — a pattern demonstrated directly in the MDA/MDE series.[8] Community sources describe 3-FEA as a weaker dopamine releaser but stronger serotonin and norepinephrine releaser compared to unsubstituted ethylamphetamine.[7]
No published EC50 values exist for 3-FEA at any transporter. All characterizations of selectivity are inferred from structural analogy. The parent compound 3-FA acts as a monoamine releaser with dopamine/norepinephrine preference and fully substitutes for methamphetamine in drug discrimination assays in mice.[11][12]
Amphetamine-class compounds are generally agonists at TAAR1 (TAAR1), which modulates monoaminergic tone. This is expected for 3-FEA by class but has not been experimentally confirmed.
Pharmacokinetics
No human pharmacokinetic data exist for 3-FEA. Bioavailability, peak plasma concentration, half-life, and protein binding are entirely uncharacterized.
By analogy with 4-fluoroamphetamine — the nearest well-studied fluoroamphetamine — the oral elimination half-life is likely in the range of 8–9 hours, with peak plasma levels approximately 2 hours after ingestion.[13] The shorter subjective duration of 3-FEA (4–6 hours oral) relative to its likely plasma half-life suggests that acute effects track the rising phase and peak concentrations rather than total elimination.
Expected metabolic pathways include N-deethylation (producing 3-fluoroamphetamine as an active metabolite with greater dopamine selectivity) and aromatic hydroxylation, likely involving CYP2D6 and CYP3A4. The meta-fluorine is metabolically stable; defluorination is not expected. Urinary excretion is the primary elimination route, with acidic urine accelerating clearance of this basic compound.inferred
Neuroscience[edit]
Neuroscience
Where it acts
As a serotonin-dominant triple releaser, 3-FEA engages multiple neural systems simultaneously. Dopamine release in the mesolimbic pathway (ventral tegmental area → nucleus accumbens) produces reward and euphoria. Serotonin flooding is expected to reduce amygdala fear reactivity and enhance prefrontal-amygdala connectivity — producing the emotional openness and warmth characteristic of entactogens.[8][14] Norepinephrine release drives sympathetic activation: elevated heart rate, blood pressure, and wakefulness.
The "paradoxical sedation" reported by users[5] is pharmacologically consistent with high serotonin release — 5-HT₁A autoreceptor activation can produce body heaviness and relaxation even against a background of catecholamine-driven stimulation. MDMA produces analogous sedating-while-stimulating phenomenology.
Why it matters
The DAT/SERT release ratio is the best predictor of abuse liability in monoamine releasers — compounds with higher dopamine selectivity show greater self-administration in animal models.[14] The inferred serotonin dominance of 3-FEA predicts moderate abuse potential, consistent with its positioning between amphetamine (high) and MDMA (moderate). The post-use dysphoria documented by Jo et al. (2024) in mice[1] fits the monoamine depletion model: supraphysiological release followed by compensatory downregulation produces a rebound effect deficit state.[15]
What is the actual DAT/SERT/NET release ratio? No in vitro data exist. Does 3-FEA produce serotonergic neurotoxicity at recreational doses? The N-ethyl substitution may confer partial protection (as shown in MDA→MDE comparisons[8]) but this is untested for 3-FEA. Does metabolic conversion to 3-FA create a biphasic experience — early serotonin-dominant phase followed by a later dopamine-dominant tail?
Subjective Effects[edit]
Subjective Effects
The experiential character of 3-FEA is defined by a tension between stimulant drive and entactogenic softness. Oral dosing produces a gradual, serotonin-forward experience — body warmth, emotional openness, and paradoxical sedation overlaid on residual stimulation — while insufflation compresses the experience into a shorter, more stimulant-dominant burst with less entactogenic depth. Set and setting sensitivity is moderate: the emotional enhancement responds to social context, but the pharmacological floor (sympathetic activation, appetite suppression, insomnia) remains fixed regardless.
Pharmacologically, 3-FEA sits closest to 4-fluoroamphetamine in the fluoroamphetamine series, sharing the mixed stimulant-entactogen character but with greater serotonin weighting pulling it toward the MDMA pole. Community consensus positions it as less euphoric and less empathogenic than MDMA at equivalent perceived doses, with a less severe post-experience deficit but also a less distinctive peak.[5]
Effect Grid
The full dual stimulant-entactogen profile expresses clearly. Emotional enhancement, empathy, and tactile euphoria become prominent. Body warmth radiates outward, music appreciation deepens substantially, and social connection feels effortless and genuine. The paradoxical sedation-over-stimulation character becomes apparent — mental energy coexists with physical relaxation.
Moderate sympathetic activation produces noticeable tachycardia and blood pressure elevation. Appetite suppression is pronounced, bruxism may begin, pupil dilation is obvious, and sweating increases. Dry mouth develops. The body high carries a serotonergic warmth distinct from pure stimulant tension.
Commitment is 4-6 hours for the primary experience, with 6-12 hours of residual aftereffects including insomnia and mild cognitive fatigue. Insufflated duration is dramatically shorter (1-2 hours total) with a more stimulant-forward character.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sound sensitivity · Visual acuity enhancement · Color enhancement
Wakefulness · Insomnia · Dry mouth · Restlessness · Heart rate perception changes · Body high · Spontaneous body sensations · Tactile euphoria · Excessive sweating · Dehydration sensation · Muscle tension · Respiratory stimulation · Tingling / electric sensations · Physical fatigue · Bruxism · Nausea · Headache · Constipation · Trembling · Nasal congestion · Laughter fits · Diarrhea · Sexual arousal enhancement · Abnormal heartbeat · Sedation · Bodily heaviness · Increased urination
Restlessness · Heart rate perception changes · Body high · Spontaneous body sensations · Tactile euphoria · Excessive sweating · Dehydration sensation · Muscle tension · Respiratory stimulation · Tingling / electric sensations · Physical fatigue · Bruxism · Nausea · Headache · Constipation · Trembling · Nasal congestion · Laughter fits · Diarrhea · Sexual arousal enhancement · Sedation · Bodily heaviness · Increased urination
Openness enhancement · Introspection enhancement · Aesthetic enhancement · Immersion enhancement · Focus enhancement · Information processing enhancement · Analysis enhancement · Thought connectivity · Cognitive flexibility · Multiple thought streams · Novelty enhancement · Creativity enhancement · Humor enhancement · Motivation suppression · Thought deceleration
Focus enhancement · Information processing enhancement · Analysis enhancement · Thought connectivity · Cognitive flexibility · Multiple thought streams · Novelty enhancement · Creativity enhancement · Humor enhancement · Motivation suppression · Thought deceleration
Anxiety · Irritability · Anhedonia · Emotional lability · Simultaneous emotions · Dysphoria · Catharsis · Anxiety suppression · Mania
Emotional lability · Simultaneous emotions · Dysphoria · Catharsis · Anxiety suppression
Trust enhancement · Emotional susceptibility · Communication enhancement · Craving · Ego inflation · Flow state
Ego inflation · Flow state
Timeline
Subtle alertness increase and faint mood shift. Peripheral stimulation begins — slight heart rate elevation and mild restlessness. Effects are sub-threshold for most subjective dimensions.
Building euphoria and body warmth emerge progressively. Sociability increases noticeably, empathogenic qualities begin manifesting. Appetite suppression and mild pupil dilation become apparent.
Full entactogenic and stimulant effects — tactile euphoria, emotional enhancement, music appreciation, and the characteristic paradoxical body sedation overlaid with mental stimulation. Empathy and social connection peak. Bruxism and cardiovascular activation at maximum.
Gradual decline in entactogenic warmth while stimulant residue persists longer. Appetite remains suppressed, mild cognitive fatigue begins. Emotional openness fades before physical stimulation resolves.
Residual stimulation, insomnia, and possible mild dysphoria. Physical fatigue accumulates while sleep remains elusive. Some users report subtle mood dip lasting into the following day.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · MDMA · cathinones
Toxicity
No human lethal dose, therapeutic index, or fatality attributable solely to 3-FEA has been established. The only published toxicological data come from Jo et al. (2024), who administered 3-FEA to mice at 1 and 10 mg/kg twice daily for 7 days without observing acute lethality.[1] No emergency department case reports or poison center notifications specific to 3-FEA have been published.
Cardiovascular toxicity
The primary safety concern is cardiovascular, based on data from the structurally related 4-fluoroamphetamine. In a retrospective analysis of 4-FA emergency presentations, severe cardiovascular complications occurred in 40% of cases — including stress cardiomyopathy, heart attack, and brain hemorrhage.[6] A controlled human study of 100 mg oral 4-FA produced marked blood pressure elevation persisting 4–5 hours; the planned higher dose arm was cancelled on safety grounds.[16]
3-FEA’s greater serotonin selectivity may theoretically reduce catecholamine-driven cardiovascular stress relative to 4-FA, but this is speculative. The norepinephrine-releasing component ensures that elevated blood pressure, rapid heart rate, and vasoconstriction remain pharmacologically expected.safety citation needed
Hyperthermia
As a serotonin-releasing agent, 3-FEA carries class-level risk of dangerous overheating, particularly when combined with physical exertion, warm environments, dehydration, or other serotonergic agents.[2]safety citation needed
Serotonergic neurotoxicity
Serotonin-releasing agents like MDMA produce brain serotonin system damage in animal models at high or repeated doses. Whether 3-FEA shares this vulnerability is unknown. The N-ethyl substitution reduced neurotoxicity in MDA→MDE comparisons,[8] which may represent a partial protective factor — untested for 3-FEA specifically.safety citation needed
Psychological risks
Expected acute psychological adverse effects include anxiety, agitation, and paranoia at high doses (driven by catecholamines) and post-use low mood, anhedonia, and depressed mood (from monoamine depletion). Jo et al. (2024) documented depression-like behavior in mice during 3-FEA withdrawal, providing animal model support for post-use mood disturbance.[1]
No data exist on 3-FEA and psychosis, though amphetamine-class stimulants as a family carry this risk at high doses or with prolonged use.
Tolerance and dependence
Physical dependence has been demonstrated in mice. Jo et al. (2024) administered 3-FEA twice daily for 7 days; withdrawal produced physical signs, hyperactivity, and depression-like behavior.[1]
Tolerance develops with repeated use. Community estimates suggest a half-life of approximately 2.5 days and full reset at approximately 5 days.[5] These values are unverified against primary literature.
Cross-tolerance is expected with other monoamine releasing agents (amphetamines, MDMA, cathinones) through transporter desensitization and monoamine depletion.[2]
Abuse potential is moderate. The parent compound 3-FA fully substitutes for methamphetamine in drug discrimination tests,[11] indicating high abuse potential for the fluoroamphetamine class. However, 3-FEA’s serotonin dominance is expected to reduce compulsive redosing relative to purely dopaminergic stimulants.[14][15]
Drug interactions
Serotonin syndrome: Combination with any agent that elevates serotonin — SSRIs, SNRIs, MAOIs, tramadol, or other serotonin releasers — creates dangerous additive serotonin accumulation. The combination with tramadol carries lethal risk: tramadol inhibits serotonin reuptake while 3-FEA forces serotonin efflux through the same transporter, producing potentially fatal serotonin syndrome.[17][18]
MAOI combinations: Absolute contraindication. Monoamine oxidase inhibition prevents breakdown of released monoamines, causing catastrophic accumulation — producing dangerous blood pressure crisis, serotonin syndrome, overheating, and death. This applies to irreversible MAOIs (phenelzine, tranylcypromine) and high-dose reversible MAOIs.[2]
Cardiovascular summation: Combination with other stimulants (cocaine, amphetamines) produces additive cardiovascular stress through compounded norepinephrine and dopamine signaling.safety citation needed
GHB/GBL: stimulation may mask the degree of CNS depression. As stimulant effects subside, rebound effect sedation from GHB/GBL could produce respiratory depression.
Contraindications
Absolute contraindications:
- MAOI therapy — concurrent or within 14 days of irreversible MAOI discontinuation[2]
- Tramadol — concurrent use[17]
Relative contraindications:
- Heart disease — high blood pressure, coronary artery disease, irregular heartbeat, history of stroke. 4-FA data document stress cardiomyopathy and heart attack at recreational doses[6]
- Concurrent serotonergic medications — SSRIs, SNRIs, lithium, triptans
- History of psychosis or mania — amphetamine-class compounds can trigger psychotic episodes
- Pregnancy — monoamine releasing agents carry risk of birth defects and neonatal withdrawal by classsafety citation needed
- Seizure disorders — amphetamine-class compounds lower seizure threshold at high doses
- Liver impairment — may prolong drug exposure if CYP-mediated metabolism is confirmedinferred
Harm Reduction[edit]
Forms & Identification
For a compound with no street-market presence and exclusively online distribution, identification challenges center on vendor reliability rather than adulterant detection. 3-FEA circulates as a white to yellowish crystalline powder and occasionally in pellet form.[3][5] The positional isomers (2-FEA, 4-FEA) and the parent compound 3-FA are visually indistinguishable from 3-FEA as powders.
Reagent testing can help exclude wrong-class substitutions but cannot distinguish between fluoroamphetamine positional isomers. A positive Marquis reaction (consistent with amphetamine class) combined with absence of darkening rules out cathinones or opioids, but confirming the specific isomer requires analytical services beyond home testing capability.
Guidelines
- Test your material — reagent kits exclude wrong-class substitutions; consider analytical services for isomer confirmation
- Weigh doses precisely — volumetric dosing or a milligram-accurate scale; do not eyeball powder
- Start low, go slow — individual response to fluoroamphetamines varies substantially; begin at the lower end of the reported range
- Time your redoses — the compulsive redosing urge is present but moderate; set a firm window (minimum 2 hours oral) and do not exceed your planned total
- Hydrate moderately — serotonin releasers impair thirst regulation; sip water steadily but do not overhydrate (hyponatremia is a risk with serotonergic agents)
- Monitor temperature — avoid strenuous activity in hot environments; take breaks from dancing; watch for signs of overheating in yourself and others
- Plan for the comedown — schedule 1–2 recovery days; avoid stacking sessions on consecutive days
- Do not mix — especially with MAOIs, tramadol, other stimulants, or serotonergic medications
Set & Setting
The mixed stimulant-entactogen profile means 3-FEA responds to social context more than pure stimulants. The emotional openness and disinhibition amplify in group settings, which can be positive (connection, communication) or destabilizing (oversharing, emotional vulnerability with strangers).
The paradoxical sedation component can produce unexpected drowsiness — planning for a stimulant night and experiencing waves of heaviness catches users off-guard. A comfortable, temperature-controlled environment with access to water and a quiet space to sit reduces risk from both the cardiovascular load and the unpredictable sedation.
Aftercare & integration. The post-experience period following serotonin-dominant releasers typically involves 1–3 days of lowered mood, fatigue, and irritability as monoamine stores replenish. This is neurochemical, not psychological failure — expecting it reduces its impact.
- Sleep: Prioritize sleep in the 48 hours following use. Melatonin or magnesium may assist if insomnia persists from residual stimulation.
- Nutrition: Appetite returns slowly. Light, nutrient-dense meals support recovery. Tryptophan-rich foods (eggs, turkey, bananas) provide serotonin precursors.
- Exercise: Gentle movement (walking, stretching) on day 2+ supports mood recovery. Avoid intense exertion on day 1.
- Social contact: Emotional openness during the experience can create a sense of social debt or vulnerability afterward. Process any intense conversations when baseline mood returns.
Recovery & Support
If use has become compulsive, frequent (multiple times per week), or is interfering with work, relationships, or health, external support is warranted. The moderate abuse potential of serotonin-dominant stimulants means dependence can develop insidiously — each session feels manageable, but the cumulative pattern erodes baseline function.
Stimulant-specific support resources include SMART Recovery (evidence-based, non-12-step), local addiction services, and harm reduction organizations that offer non-judgmental counseling. A GP or psychiatrist can assess whether the post-use mood deflation has become a standalone depressive episode requiring treatment.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain or crushing pressure
- Seizure or loss of consciousness
- Body temperature hot to the touch through clothing
- Severe confusion, inability to speak coherently
- Rigid muscles combined with high fever (serotonin syndrome)
Immediate steps:
- Call emergency services immediately if any of the above are present
- Move the person to a cool, quiet space
- Remove excess clothing; apply cool (not ice-cold) water to skin
- If unconscious but breathing, place in the recovery position
- Do NOT restrain a seizing person — protect their head, clear the area
- Do NOT induce vomiting
What to tell the dispatcher: Name the substance (3-FEA / fluoroethamphetamine), approximate dose and time taken, current symptoms, and any other substances consumed. Good Samaritan laws in many jurisdictions protect people who call for help during drug emergencies.
Legal Status[edit]
Legal Status
3-FEA occupies a complex regulatory position globally. As a novel psychoactive substance without therapeutic application, it is not individually scheduled in most jurisdictions but falls under structural analog provisions or blanket NPS legislation in several. The regulatory trend is toward increasing control — Germany scheduled it pre-emptively in 2016, and the DEA’s 2026 scheduling of the positional isomer 4-FA signals intensifying scrutiny of the fluoroamphetamine class.[19]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled (analog) | Federal Analogue Act may apply as Schedule II analog of amphetamine. 4-FA placed in Schedule I effective February 17, 2026; 3-FEA not yet named but prosecution under analog act is possible for human consumption[19] |
| United Kingdom | Class A | Covered by amphetamine analog clause under the Misuse of Drugs Act 1971[7] |
| Germany | Controlled | Neue-Psychoaktive-Substanzen-Gesetz (NpSG), effective November 26, 2016[7] |
| Netherlands | Controlled | Scheduled as of July 1, 2025[7] |
| Austria | Controlled | Neue-Psychoaktive-Substanzen-Gesetz Österreich (NPSG) |
| Switzerland | Controlled | Defined derivative of α-methylphenethylamine under Verzeichnis E point 130; legal for scientific/industrial use[7] |
| Canada | Controlled (analog) | Considered Schedule I analog of amphetamine under CDSA |
| Australia | Not explicitly scheduled | Analog provisions under Standard for Uniform Scheduling of Medicines and Poisons may apply |
| France | Not explicitly scheduled | Not individually controlled as of December 2024; generic scheduling provisions may apply |
Analog act considerations
In the United States, the Federal Analogue Act (21 USC §813) treats substances "substantially similar" to Schedule I or II controlled substances as controlled when intended for human consumption. 3-FEA is structurally substantially similar to amphetamine (Schedule II) and methamphetamine (Schedule II), differing only by a meta-fluorine and N-ethyl substitution. The 2026 placement of 4-FA in Schedule I further strengthens the analog argument for fluoroamphetamine derivatives. Possession marketed as a "research chemical" with explicit not-for-human-consumption labeling has historically provided ambiguous legal protection.
references
- [1]
- [2]
- [3] ^abcdYanini Á, Armenta S, Esteve-Turrillas F, Galipienso N, de la Guardia M (2018) Identification and characterization of the new psychoactive substance 3-fluoroethamphetamine in seized material — Forensic Toxicology doi:10.1007/s11419-018-0416-y
- [4] ^abLiechti ME (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling — Swiss Medical Weekly doi:10.4414/smw.2015.14043
- [5]
- [6] ^abcGresnigt FMJ, Snik A, Franssen EJF, Vanhommerig JW, de Lange DW, Riezebos RK (2022) 4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis — Journal of the American College of Emergency Physicians Open doi:10.1002/emp2.12813